Kratom (Mitragyna speciosa): FDA Regulatory Status, State Bans & 7-OH Scheduling

What Is Kratom?

Kratom (Mitragyna speciosa) is a tropical tree in the coffee family (Rubiaceae) native to Southeast Asia, primarily Thailand, Malaysia, Indonesia, Myanmar, and Papua New Guinea. Its leaves have been used for centuries in traditional medicine as a stimulant at low doses and an analgesic at higher doses.

Property	Value
Botanical Name	Mitragyna speciosa Korth.
Family	Rubiaceae
UNII (mitragynine)	ISP41580TL
CAS Number (mitragynine)	4098-40-2
Primary Alkaloids	Mitragynine (~60% of alkaloid content), 7-hydroxymitragynine (<2% in raw leaf)

The pharmacological interest centers on two indole alkaloids: mitragynine and 7-hydroxymitragynine (7-OH). Research indicates 7-OH binds to mu-opioid receptors with approximately 13 times the potency of morphine, making it the primary driver of kratom's analgesic effects. The distinction between whole-leaf kratom and concentrated 7-OH products has become the central fault line in the current regulatory debate.

The American Kratom Association estimates 10 to 16 million Americans use kratom regularly. Products range from traditional powdered leaf and capsules to concentrated extracts, shots, gummies, and drink mixes — many formulated with elevated or synthetic 7-OH levels that bear little resemblance to the traditional botanical.

FDA Regulatory Status

The FDA's position on kratom is unambiguous: kratom is not approved for any use — not as a drug, not as a dietary supplement, not as a food additive.

Three Legal Determinations

1. Adulterated Dietary Supplement: Kratom is a new dietary ingredient (NDI) for which there is "inadequate information to provide reasonable assurance" of safety. Any supplement containing kratom is adulterated under Section 402(f) of the FD&C Act.

2. Unsafe Food Additive: When added to food or beverages, kratom is treated as an unsafe food additive — no GRAS determination, no food additive petition.

3. Unapproved New Drug: When marketed with therapeutic claims (opioid withdrawal, pain, depression), kratom products become unapproved new drugs.

Import Alert 54-15

The FDA's primary enforcement mechanism is Import Alert 54-15, which authorizes Detention Without Physical Examination (DWPE) for dietary supplements and bulk ingredients containing kratom. First published in 2012, republished most recently in February 2025. Dozens of firms appear on the Red List.

The 7-OH Escalation (July 2025)

On July 29, 2025, HHS Secretary Robert F. Kennedy Jr. announced a federal crackdown on concentrated 7-hydroxymitragynine products as part of MAHA. The FDA simultaneously:

• Issued seven warning letters to companies marketing concentrated 7-OH products: Shaman Botanicals, My Smoke Wholesale, Relax Relief Rejuvenate Trading, Thang Botanicals (7OHMZ), Royal Diamond Imports, Hydroxie, and 7Tabz Retail
• Formally recommended to the DEA that 7-hydroxymitragynine be classified as a Schedule I controlled substance

The FDA specifically targeted products marketed to young consumers — fruit-flavored gummies, ice cream cones, and brightly packaged shots sold in gas stations and smoke shops. Kennedy positioned the crackdown as part of the administration's war on addiction.

Critical distinction: The scheduling recommendation applies to 7-hydroxymitragynine as an isolated compound, not to the kratom plant itself.

Key Deadlines

Date	Event	Type
August 2016	DEA announces intent to schedule mitragynine and 7-OH as Schedule I	Federal
October 2016	DEA withdraws scheduling intent after 23,000+ comments and congressional pushback	Federal
April 2018	FDA orders first mandatory recall of kratom (Triangle Pharmanaturals, salmonella)	Federal
February 2025	FDA republishes Import Alert 54-15	Federal
July 15, 2025	FDA issues 7 warning letters to 7-OH product companies	Federal
July 29, 2025	HHS/FDA recommend Schedule I for 7-OH	Federal
August 1, 2025	Louisiana kratom ban takes effect (SB 154)	State
April 1, 2026	Rhode Island KCPA takes effect (first ban reversal)	State
2027 (est.)	DEA rulemaking on 7-OH scheduling expected to conclude	Federal

The DEA's 2016 Scheduling Attempt

On August 31, 2016, the DEA published a notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into Schedule I. What followed was unprecedented:

• 23,000+ public comments — vast majority opposing
• 50+ members of Congress signed a bipartisan letter urging halt
• Mass public demonstrations

On October 12, 2016, the DEA withdrew its notice — the first time the agency had ever reversed a scheduling decision after announcing it. The 2016 episode established a critical political precedent: there is a large, organized constituency opposing kratom prohibition. This is why the 2025 federal action focused narrowly on concentrated 7-OH rather than the kratom plant itself.

State-Level Regulation

States with Complete Bans

State	Year	Notes
Alabama	2016	Kratom alkaloids classified as Schedule I
Arkansas	2016	Controlled substance schedules
Indiana	2014	Banned under synthetic drug statutes
Vermont	2016	Complete statewide ban
Wisconsin	2014	Mitragynine and 7-OH listed as Schedule I
Louisiana	2025	SB 154 effective August 1, 2025; up to 5 years imprisonment

The Rhode Island Reversal

Rhode Island became the first state in U.S. history to reverse a kratom ban. Banned since 2017, the governor signed a KCPA in July 2025 replacing the ban with a regulated framework effective April 1, 2026 — including 21+ age restrictions, labeling requirements, testing mandates, and licensing.

Kratom Consumer Protection Acts (KCPAs)

Over 20 states have enacted some version of the KCPA, including Utah, Georgia, Arizona, Nevada, Oregon, Colorado, Florida, Oklahoma, Maryland, Kentucky, Mississippi, South Carolina, West Virginia, and Missouri. Key provisions typically include:

• Age restrictions (18+ or 21+)
• Labeling requirements (alkaloid content disclosure)
• Adulteration prohibitions (synthetic alkaloids banned, 7-OH typically capped at 2%)
• Testing mandates (heavy metals, pesticides, microbial, alkaloid content)
• Registration or licensing

7-OH State Actions

• Florida: Emergency rule scheduling 7-OH as Schedule I (August 2025)
• Louisiana: SB 154 covers both kratom and 7-OH
• Mississippi and Colorado: Banned synthetic 7-OH specifically (2025)

International Status

Indonesia: The Supply Chain Earthquake

Indonesia has historically supplied ~95% of the world's kratom exports. In October 2024, Trade Minister Regulation No. 20 prohibited export of raw/semi-processed kratom, required sterilization, and set minimum mitragynine concentrations. Impact: crushed-leaf prices increased 100-400%.

Thailand: From Prohibition to Regulation

Thailand legalized kratom in 2021 after banning it since 1943. The Kratom Plant Act of 2022 established a comprehensive framework for cultivation, manufacturing, trade, and consumption.

Other Jurisdictions

• Australia: Schedule 9 (prohibited substance)
• United Kingdom: Banned under Psychoactive Substances Act 2016
• Malaysia: Controlled under Poisons Act 1952
• EU: No EU-wide ban; several member states have restrictions
• WHO: Never formally reviewed or scheduled kratom

Affected Product Categories

• Dietary supplements — Capsules, tablets, powders, tinctures. FDA position: adulterated.
• Functional beverages and shots — Concentrated kratom/7-OH products in gas stations. Driving current federal enforcement.
• Gummies and edibles — Rapidly growing; 7-OH gummies specifically targeted in July 2025 warning letters.
• Bulk botanical ingredients — Subject to Import Alert 54-15.
• Herbal teas — FDA position: adulterated food if sold for human consumption.

What Companies Should Do

1. Understand Your Exposure

Assess where kratom touches your business — manufacturing, distribution, retail, shared equipment, or supply chain adjacency.

2. Monitor the 7-OH Scheduling Process

The DEA's 18-24 month rulemaking will determine whether 7-OH becomes Schedule I. The moment it's scheduled, any product with detectable 7-OH becomes a controlled substance. Plan for that scenario now.

3. Track State-Level Changes

Maintain a current state-by-state legality matrix. Implement geolocation-based shipping restrictions for e-commerce. Watch the Rhode Island KCPA (April 1, 2026) as a model.

4. Formulation and Labeling Compliance

In KCPA states: ensure 7-OH concentration is at or below naturally occurring levels (<2%), test every batch, label with full alkaloid disclosure, never make therapeutic claims.

5. Supply Chain Due Diligence

Indonesia's 2024 export restrictions have fundamentally altered the supply chain. Verify supplier compliance, evaluate alternative sourcing from Thailand, maintain COAs for every lot.

Regulatory Intelligence

Policy Canary tracks FDA warning letters, import alerts, state legislation, and federal rulemaking actions affecting kratom and hundreds of other substances. Subscribe to receive alerts when new regulatory actions affect your products.